INBX - Inhibrx Biosciences, Inc.
NEXT EARNINGS:
Mar 16, 2026
(in 19 days)
EPS Est: $-2.08
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
Market Cap:
1.16B
Volume:
230,812
Avg Volume:
208,173
52 Week Range:
10.805-94.565
Sector:
Healthcare
Industry:
Biotechnology
Beta:
1.36
Last Dividend:
$0.85
Exchange:
NASDAQ
Country:
US
Employees:
156
IPO Date:
2024-06-04
EPS (TTM):
116.58
P/E Ratio:
0.13
Revenue (TTM):
200,000
Total Assets:
180.77M
Total Debt:
8.05M
Cash & Equiv:
152.60M
Rev Growth (5Y):
-53.4%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
1214.7%
Debt/Equity:
0.06
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-14 | $-2.28 | $-2.08 | -9.6% | — | — | — |
| 2025-08-13 | $-1.85 | $-2.92 | +36.6% | $1.3M | — | — |
| 2025-05-14 | $-2.80 | $-2.55 | -9.8% | — | — | — |
| 2025-03-17 | $-3.09 | $-2.88 | -7.3% | $100000 | — | — |
| 2024-11-14 | $-2.84 | $-3.06 | +7.2% | — | — | — |
| 2024-08-13 | $125.48 | $-3.60 | +3585.6% | $100000 | — | — |
| 2024-06-03 | $-1.44 | $-1.04 | -38.5% | — | $50000 | — |
| 2024-02-28 | $-1.73 | $-1.07 | -61.7% | $1.6M | $50000 | +3168.0% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 200,000 | 1.80M | 2.19M | 7.12M | 12.81M | 9.09M | 7.50M | 7.95M | 6.67M |
| Net Income | 1.69B | (241.36M) | (145.23M) | (81.77M) | (75.64M) | (51.40M) | (31.16M) | (19.44M) | (8.27M) |
| EPS | 116.58 | -5.12 | -3.62 | -2.15 | -2.99 | -1.41 | -1.15 | -0.68 | -0.23 |
| Total Assets | 180.77M | 307.89M | 290.88M | 150.45M | 143.74M | 26.49M | 9.98M | 17.25M | 21.27M |
| Total Debt | 8.05M | 210.14M | 207.10M | 72.14M | 37.45M | 41.73M | 9.49M | 14.66M | 18.92M |
| Cash & Equivalents | 152.60M | 277.92M | 273.87M | 131.30M | 128.66M | 11.54M | 2.10M | 13.47M | 20.02M |
| Operating Cash Flow | (194.41M) | (193.31M) | (115.30M) | (80.32M) | (47.97M) | (32.08M) | (23.09M) | (18.75M) | (18.11M) |
| Free Cash Flow | (197.01M) | (197.90M) | (115.99M) | (81.19M) | (49.33M) | (33.89M) | (24.52M) | (20.09M) | (18.32M) |
| FCF per Share | -13.61 | -4.20 | -2.89 | -2.14 | -1.95 | -0.93 | -0.91 | -0.70 | -0.50 |
| Book Value | 133.58M | 43.50M | 58.06M | 52.38M | 75.47M | (93.57M) | (57.64M) | (28.77M) | (9.25M) |
| Cash & ST Investments | 152.60M | 277.92M | 273.87M | 131.30M | 128.66M | 11.54M | 2.10M | 13.47M | 20.02M |
| ROC Equity | 12.63 | -5.55 | -2.50 | -1.56 | -1.00 | N/A | N/A | N/A | N/A |